Study: Ajmani 2026, Journal of the American Academy of Dermatology
Scarring Alopecias Part 2: Treatments
Citation
Ajmani S, Klufas D et al (2026). Journal of the American Academy of Dermatology. PubMed id 43009060.
Cards that cite this study (1)
Each card gives its own wording for who was tested, how and what was found.
- CCCA: scarring hair loss at the crown Tier B thin
B Review of scarring alopecias (n=not stated)
Narrative review of treatments.
There are no FDA-approved therapies for primary scarring alopecias; all treatments are off label. Lymphocytic types including CCCA may respond to immunomodulatory agents, and the aims are to halt inflammation, relieve symptoms and preserve follicles. Minoxidil and similar agents are used as camouflage.
As recorded in this card: Ajmani S, Klufas D et al (2026), Journal of the American Academy of Dermatology, [review]
Note: Review of treatments used; the abstract does not report a randomised trial for CCCA.
This is information, not medical advice. If you are worried, see a doctor or pharmacist. How we grade the evidence. All studies.